

**Remarks**

The present invention is directed to compositions and methods for immunization against an allergen. Claims 1-27 are currently pending.

**Restriction Requirement**

In the Restriction Requirement dated October 9, 2007, the Examiner restricted the claims into sixteen groups as follows and requires election of one of the following groups of claims for examination and prosecution.

Group I: Claims 1-15 drawn to recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Blo t 5 allergen.

Group II: Claims 1-15 drawn to recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Blo t 1 allergen.

Group III: Claims 1-15 drawn to recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der p 1 allergen.

Group IV: Claims 1-15 drawn to recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der p 2 allergen.

Group V: Claims 1-15 drawn to recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der p 3 allergen.

Group VI: Claims 1-15 drawn to recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der f1 allergen.

Group VII: Claims 1-15 drawn to recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der f2 allergen.

Group VIII: Claims 1-15 drawn to recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der f3 allergen.

Group IX: Claims 16-27 drawn to methods for immunization against an allergen by administering a recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Blo t 5 allergen.

Group X: Claims 16-27 drawn to methods for immunization against an allergen by administering a recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Blo t 1 allergen.

Group XI: Claims 16-27 drawn to methods for immunization against an allergen by administering a recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der p 1 allergen.

Group XII: Claims 16-27 drawn to methods for immunization against an allergen by administering a recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der p 2 allergen.

Group XIII: Claims 16-27 drawn to methods for immunization against an allergen by administering a recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der p 3 allergen.

Group XIV: Claims 16-27 drawn to methods for immunization against an allergen by administering a recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der f1 allergen.

Group XV: Claims 16-27 drawn to methods for immunization against an allergen by administering a recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der f2 allergen.

Group XVI: Claims 16-27 drawn to methods for immunization against an allergen by administering a recombinant nucleic acid comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der f3 allergen.

In response to the Restriction Requirement, Applicant elects Group XI directed to methods for immunization against an allergen by administering a recombinant nucleic acid

comprising a gene encoding a first signal peptide operably linked to a gene encoding a Der p 1 allergen.

The Applicant reserves the right to file any number of divisional applications to the remaining non-elected groups listed above having the same priority date as the present application.

• **Election of Species**

Regardless of which of Groups I-XVI is elected, Applicants were also required to elect a single species, *for search purposes only*, for the following groups of species, to which the claims would be restricted if no generic claim is finally held allowable.

I. If any of Groups I to XVI are elected, Applicants were required to elect a single specific nucleic acid comprising a first signal peptide (as recited in claims 3-4 and 9) and a second signal peptide (as recited in claims 6-7 and 9).

• In response to the election of species requirement for a first signal peptide, Applicants elect the species of the N-terminal signal peptide of LAMP-1, being part of SEQ ID NO:5, i.e. the chimeric gene that encodes the *Mus musculus* LAMP-1 leader sequence, the entire Der p 1 gene product and the *Mus musculus* LAMP-1 transmembrane and cytoplasmic domain, for search purposes only. Applicants understand that if a generic claim is found free of prior art, the remaining species will be searched. Of elected claims 16-27, claims 16-27 are generic to this first signal peptide.

In response to the election of species requirement for a second signal peptide, Applicants elect the species of the C-terminal lysosome or endosome targeting sequence of LAMP-1; being part of SEQ ID NO:5, for search purposes only. Applicants understand that if a generic claim is

**RESPONSE TO RESTRICTION REQUIREMENT**

U.S.S.N. 10/526,120

found free of prior art, the remaining species will be searched. Of elected claims 16-27, claims 16-27 are generic to this second signal peptide.

*II.* If Groups IX to XVI are elected, then Applicants were required to elect a single species of specific mode of administration (as recited in claims 20-21, 23 and 26).

Applicants elect the species of intramuscular administration, for search purposes only, with the understanding that if a generic claim is found free of prior art, the remaining species will be searched. Of elected claims 16-27, claims 16-27 are generic to this specific mode of administration.

### Conclusions

Applicants submit that the response herein provides a complete response to the Restriction Requirement dated October 9, 2007.

If the Examiner believes there are other issues that may be resolved by telephone interview, or that there are any informalities remaining in the application that may be corrected by Examiner's Amendment, a telephone call to the undersigned is respectfully solicited.

No additional fees are believed due, however the Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment of fees to Deposit Account number 11-0980.

Respectfully submitted,



---

Stephen C. MacDonald, Ph.D.  
Reg. No. 60,401

Date: February 4, 2008

King & Spalding LLP  
1180 Peachtree Street  
Atlanta, Georgia 30309-3521  
404-572-2715 (telephone)  
404-572-5135 (facsimile)